Lithuania Pharmaceuticals and Healthcare Report Q1 2013

Publisher Name :
Date: 16-Jan-2013
No. of pages: 96

We continue to hold our subdued outlook for the Lithuanian pharmaceuticals market during the next few years, on account of the changing economic and demographic situation. We expect limited low single digit growth in 2012, with the market expected to increase by a local currency margin of 2.5 %year-on-year (y-o-y) to reach LTL1.68bn (US$618mn) in 2012 at consumer prices. However, in US dollar terms, the market's value will shrink by 6.3%, indicating the challenges facing companies operating in the market.

Headline Expenditure Projections


  • Pharmaceuticals:LTL1.64bn (US$659mn) in 2011 to LTL1.68bn (US$618mn) in 2012; +2.5 %in local currency terms and -6.3% in US dollar terms. Forecast slightly up from Q412 on account of new macroeconomic data.

  • Healthcare:LTL6.99bn (US$2.81bn) in 2011 to LTL7.29bn (US$2.68bn) in 2012; +4.3% in local currency terms and -4.7% in US dollar terms. Forecast slightly up from Q412 on account of new macroeconomic data.

  • Medical devices:LTL679mn (US$273mn) in 2011 to LTL749mn (US$276mn) in 2012; +10.3% in local currency terms and +0.8% in US dollar terms. Forecast slightly up from Q412 on account of new macroeconomic data.


Risk/Reward Rating:

In our Q113 Pharmaceuticals Risk/Reward Rating (RRR) matrix, Lithuania is 15th, out of the 20 markets surveyed in Emerging Europe, below its Baltic peers. Although Lithuania boasts a largely risk-free operating environment, its muted rewards prospects will continue to impact its standing in the regional matrix. Globally, Lithuania ranks 60th out of 95 markets surveyed.

Key Trends and Developments

In October 2012, Seimas of the Homeland Union-Lithuanian Christian Democrats (TS-LKD) faction George Razma appealed the government to reconsider additional funding of LTL60.0mn (US$22.7mn) for healthcare institutions in the country. Lithuanian patients have to pay extra for medical services that should be available for free, Razma said. The additional funds are expected to partially solve the issue of lack of funding for treatment services. Razma asked the government to evaluate the proposal after considering the difficult situation of Lithuania's hospital system.

BMI Economic View:

We have revised up our growth outlook for 2013 economic growth on account of improved financing conditions and signs of a tightening labour market. However, Lithuania's construction sector remains a long way off from a meaningful recovery, and coupled with a weak external climate, we maintain a tepid outlook for the economy over the coming years.

BMI Political View:

Controversy surrounding an ongoing criminal investigation into key members of a majority newly-elected coalition party means that the incoming administration of Prime Ministerdesignate Algirdas Butkevicius will be under enormous pressure to acquire political credibility by honouring its anti-austerity mandate. Although we have long accounted for a looser fiscal policy in our view that Lithuania would continue to progress towards euro adoption, the risk of major coalition instability and a rift with the president's office threatens to force the government into a far more aggressive policy direction than under our current baseline scenario.

Lithuania Pharmaceuticals and Healthcare Report Q1 2013

Table of Contents

Executive Summary  6
SWOT Analysis  8
Lithuania Pharmaceuticals And Healthcare Industry SWOT  8
Lithuania Political SWOT  9
Lithuania Economic SWOT  9
Lithuania Business Environment SWOT  10
Pharmaceuticals Risk/Reward Ratings  11
Table: Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings, Q113  11
Rewards  12
Risks  12
Lithuania - Market Summary  14
Regulatory Regime  15
Regional Harmonisation  16
Pharmaceutical Advertising  17
Intellectual Property Developments  18
Pricing Regime  19
Pricing Developments  20
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines 22
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines 23
Reimbursement Regime  23
Reimbursement Developments  24
Industry Developments 26
Epidemiology  26
Table: Leading Causes of Death, 2002-2010  27
Communicable Diseases  27
Table: Selected Notifiable Infectious Diseases, 2004-2010 28
Table: Incidence of HIV & AIDS, 2002-2010  29
Healthcare System  29
Healthcare Provision  29
Table: Inpatient Institutions & Hospital Beds by Sector, 2000-2010  30
Table: Outpatient Facilities by Type, 2003-2010  30
Healthcare Funding  31
Healthcare Insurance  32
E-Health  32
Clinical Trials  33
Biotechnology  34
Recent Biotechnology Sector Developments  35
Medical Devices 36
Industry Forecast Scenario  37
Pharmaceutical Market Forecast  37
Table: Pharmaceutical Sales Indicators 2008-2016  38
Healthcare Market Forecast  39
Table: Healthcare Expenditure Indicators 2008-2016  40
Table: Healthcare Governmental Indicators 2008-2016  41
Table: Healthcare Private Indicators 2008-2016  41
Key Growth Factors - Macroeconomic  42
Table: Economic Activity  51
Prescription Drug Market Forecast  52
Table: Prescription Drug Sales Indicators 2008-2016  54
Patented Drug Market Forecast  55
Table: Patented Drug Market Indicators 2008-2016  56
Generic Drug Market Forecast  57
Table: Generic Drug Sales Indicators 2008-2016  58
OTC Medicine Market Forecast  59
Table: OTC Medicine Sales Indicators 2008-2016  60
Pharmaceuticals Trade Forecast 61
Table: Exports and Imports Indicators 2008-2016  62
Medical Device Market Forecast 63
Table: Medical Devices Sales Indicators 2008-2016  63
Key Risks To BMI's Forecast Scenario  64
Competitive Landscape  65
Pharmaceuticals Sector 65
Table: Members of the Association of Manufacturers of Drugs (VGA), 2011  65
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA)  66
Domestic Industry  66
Pharmaceutical Wholesale  67
Pharmaceutical Retail  68
Table: Pharmacies, 2000-2010  69
Pharmaceutical Distribution Developments  70
Company Profiles  72
Local Companies  72
Valentis  72
Sanitas (Valeant)  74
Sicor Biotech (Teva)  77
Multinational Companies  79
GlaxoSmithKline  79
Pfizer 81
Novartis  82
Merck & Co  83
Sanofi 84
Demographic Outlook  85
Table: Lithuania's Population By Age Group, 1990-2020 ('000)  86
Table: Lithuania's Population By Age Group, 1990-2020 (% of total) 87
Table: Lithuania's Key Population Ratios, 1990-2020  88
Table: Lithuania's Rural And Urban Population, 1990-2020 88
Glossary  89
BMI Methodology  91
How We Generate Our Pharmaceuticals Industry Forecasts 91
Pharmaceuticals Risk/Reward Ratings Methodology 92
Ratings Overview  92
Table: Pharmaceutical Business Environment Indicators  93
Weighting  94
Table: Weighting Of Components  94

List of Tables

Table: Central And Eastern Europe Pharmaceuticals Risk/Reward Ratings, Q113
Table: Wholesale Mark-Ups For Reimbursed And Non-Reimbursed Medicines
Table: Retail Mark-Ups For Reimbursed And Non-Reimbursed Medicines
Table: Leading Causes of Death, 2002-2010
Table: Selected Notifiable Infectious Diseases, 2004-2010
Table: Incidence of HIV & AIDS, 2002-2010
Table: Inpatient Institutions & Hospital Beds by Sector, 2000-2010
Table: Outpatient Facilities by Type, 2003-2010
Table: Pharmaceutical Sales Indicators 2008-2016
Table: Healthcare Expenditure Indicators 2008-2016
Table: Healthcare Governmental Indicators 2008-2016
Table: Healthcare Private Indicators 2008-2016
Table: Economic Activity
Table: Prescription Drug Sales Indicators 2008-2016
Table: Patented Drug Market Indicators 2008-2016
Table: Generic Drug Sales Indicators 2008-2016
Table: OTC Medicine Sales Indicators 2008-2016
Table: Exports and Imports Indicators 2008-2016
Table: Medical Devices Sales Indicators 2008-2016
Table: Members of the Association of Manufacturers of Drugs (VGA), 2011
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA)
Table: Pharmacies, 2000-2010
Table: Lithuania's Population By Age Group, 1990-2020 ('000)
Table: Lithuania's Population By Age Group, 1990-2020 (% of total)
Table: Lithuania's Key Population Ratios, 1990-2020
Table: Lithuania's Rural And Urban Population, 1990-2020
Table: Pharmaceutical Business Environment Indicators
Table: Weighting Of Components

  • Overview of Global and Chinese 3D Printing Market 2015-2020
    ‘2015 3D Printing Industry Report -Global and Chinese Market’ is a comprehensive research report that describes the scope of the Global and Chinese 3D printing industry, analyzing the end-users behavior and the latest industry trends. Also, the report evaluates the growth prospects and the up-coming opportunities in the industry over the forecast period of 2015-2020. [...]
  • Schottky Diode Industry Research – 2015 Global and Chinese Market Overview
    ‘2015 Schottky Diode Industry Report – Global and Chinese Market Scenario’ is a top-notch research report, delivering premium industry insights and explanations of complex business scenarios. The report systematically articulates various growth prospects and current market challenges being faced by the existing industry players. The research report also drafts a meticulous business forecast that provides [...]
  • Codeine (CAS 76-57-3) Industry Research Report – 2009-2019 Market Forecast
    ‘Global and Chinese Codeine (CAS 76-57-3) Industry, 2009-2019 Market Research Report’, a systematically structured research report, that aims to deliver a detailed understanding of vivid market scenarios prevalent in the Codeine (CAS 76-57-3) industry to the user.  The report articulates various sections that thoroughly describe all key-aspects of the Codeine (CAS 76-57-3) industry. The report [...]
  • Global and Chinese Mainframe Banking Industry 2015 Outlook
    2015 Banks Mainframe Industry Report -Global and Chinese Market is a detailed market research report, delivering premium industry insights and analyzing the growth prospects of the industry over the forecast period of 2015-2020. The systematically structured sections of the research report, aims at conveying a strong business understanding to the user, enhancing the decision making [...]
  • Global and Chinese Market Situation of Milk Infant Formula Industry Over the Period of 2009-2019
    ‘Market Research Report on Global and Chinese Milk Infant Formula Industry, 2009-2019’ a comprehensive market study, that analyses various market landscape and key-aspects of the industry, delivering premium business insight and thorough understanding of the Global and Chinese market conditions to the user. Industry experts have methodologically structured the elaborative sections of the research report, [...]
    • The Oil Drilling Rig Industry
    • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and se…

    • HER2-Negative Breast Cancer’s Therapeutic Market
    • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can …

    • The Market of Plate Heat Exchanger
    • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitat…

    • The Industry of Binding Machines
    • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the bind…

    • The Boom In Women Infertility Market
    • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Latvia Pharmaceuticals and Healthcare Report Q3 2012
    Published: 08-May-2012        Price: US 1295 Onwards        Pages: 80
    BMI View: We have revised downwards our 2012 projections for the growth of the Latvian pharmaceutical market on account of weaker growth towards the end of 2011, combined with ongoing concerns over the external economic environment in Europe, which will not be supportive of Latvian exports and therefore economic growth. We forecast 4.3% year-on-year (y-o-y) local currency growth in 2012, with the market expected to be valued at LVL296mn (US$540mn) by the end of the year. Risks are mostly to the ......
  • Nigeria Pharmaceuticals and Healthcare Report Q3 2012
    Published: 08-May-2012        Price: US 1295 Onwards        Pages: 101
    BMI View: The Nigerian pharmaceutical market continues to be seen as a risky proposition to multinationals. While the country’s oil revenues are significant, income distribution remains extremely uneven, resulting in per capita spending on medicines of under US$10 per annum, most of which is met through private funding. Affordability of pharmaceuticals has come under further pressure due to the January 2012 removal of fuel subsidies, which have resulted in higher inflation and increased produc......
  • Sweden Pharmaceuticals and Healthcare Report Q3 2012
    Published: 08-May-2012        Price: US 1295 Onwards        Pages: 72
    BMI View: Our five-year forecasts for the Swedish pharmaceutical market show a decline in its overall size, which is expected to fall to SEK42.02bn (US$5.64bn) by 2016. Key reasons for this pessimism include patent expirations and the subsequent entry of copy products, coupled with the government’s focus on cost containment through measures that will encourage the consumption of cheaper generic medicines. Nevertheless, population ageing as well as continued growth will continue to promote the ......
  • Tanzania Pharmaceuticals and Healthcare Report Q3 2012
    Published: 08-May-2012        Price: US 1295 Onwards        Pages: 43
    BMI View: It is vital the Tanzanian government assesses its medicine procurement systems. The expiry of medicines does not bode well for the state and its high reliance on donor funding for the healthcare sector, particularly as reports have highlighted the poor availability of essential medicines in the country. Furthermore, we believe the investment in improving the medicine procurement process will increase Tanzania's attractiveness as a location in which to sell medicines. Headline Expendi......
  • Australia Pharmaceuticals and Healthcare Report Q3 2012
    Published: 08-May-2012        Price: US 1295 Onwards        Pages: 100
    BMI View: Given the country’s increasingly ageing population and the consequential rise in noncommunicable diseases, Australia is a highly attractive place for multinational companies despite lower growth potential compared to emerging markets. However, we caution that the government’s funding of the Pharmaceutical Benefits Scheme (PBS) may be unsustainable, compounded by a lacklustre economic growth that may pose threats to the pharmaceutical industry if the government were to pursue aggres......
  • Turkey Pharmaceuticals and Healthcare Report Q3 2012
    Published: 15-May-2012        Price: US 1295 Onwards        Pages: 102
    BMI View: Before 2010, Turkey's pharmaceutical market growth was rapidly driven by modernisation, growing investment and improving awareness about healthcare. Since 2009, Turkey's pharmaceutical industry has been beset by government-imposed price controls and the worsening economic environment has moderated some of the more optimistic outlooks for this market. The drug market in 2012 will be defined by the price cutting and public discount decree announced in November 2011, though we note the mo......
  • Bangladesh Pharmaceuticals and Healthcare Report Q4 2012
    Published: 10-Oct-2012        Price: US 1295 Onwards        Pages: 91
    BMI View: While geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies, such as Bangladesh, may be a favourable strategy for any multinational pharmaceutical company - it is vital that a company recognises both the rewards and the risks present in a market. With regards to assessing risks in the Bangladeshi healthcare sector, we have identified those emanating from the state's political/economic profile (such as high inflation) and indus......
  • Estonia Pharmaceuticals and Healthcare Report Q4 2012
    Published: 10-Oct-2012        Price: US 1295 Onwards        Pages: 77
    BMI View: We continue to view Estonia as a low-potential market, largely on account of its small - and gradually declining - population. Short-term development of its pharmaceutical market will be shaped by the factors including prevailing economic conditions, patent expirations and government encouragement of the consumption of cheaper generic medicine. We expect imports to remain of crucial importance to market supply, with Estonia lacking a major domestic drug producer and with local rese......
  • West and Central Africa Pharmaceuticals and Healthcare Report Q4 2012
    Published: 10-Oct-2012        Price: US 1295 Onwards        Pages: 90
    BMI View: We hold to our view that Cameroon's medium-to-long-term drug market expansion potential remains highly dependent on the country's economic growth and is strongly linked to rising income and greater consumer purchasing power. We see Cameroon enjoying above-trend real GDP growth for the next several years as new oil production and a set of major new investments give a temporary boost to the economy. However, the government has limited funds to make the investment needed to improve th......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs